The deal prepares for a pain treatment market rivalry with Vertex Pharmaceuticals as the industry starts to move away from ...

The acquisition expands Lilly’s pain pipeline with a slate of drugs targeting ion channel proteins like NaV1.7 and NaV1.8.

Eli Lilly will buy privately held SiteOne Therapeutics in a deal worth as much as $1 billion, the companies said on Tuesday, ...

After a fourth quarter in which revenue boomed throughout the biopharma industry, there were reversals for several drugmakers ...

Transaction will augment Lilly's efforts to advance non-opioid medicines for pain management INDIANAPOLIS, May 27, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: ...

Eli Lilly has agreed to acquire the pain-treatment company SiteOne Therapeutics for up to $1 billion in cash. The drug company said Tuesday that the acquisition includes SiteOne's STC-004, which is ...

Eli Lilly and Company (NYSE:LLY) is expanding its neuroscience pipeline through the acquisition of SiteOne Therapeutics in a deal worth up to $1 billion, deepening its bet on non-opioid pain ...

Plus, hedge fund investor Ken Griffin gave $10 million to NYU Langone Health to create a center that will offer programs ...

Eli Lilly's growth is impressive, but its current valuation is only justifiable with sustained high growth. Click here to ...

Eli Lilly will buy privately held SiteOne Therapeutics in a deal worth as much as $1 billion, the companies said on Tuesday, ...

Weight loss drugs like Wegovy and Zepbound are getting cheaper, if you are willing to pay out of pocket for the medications.

The U.S. imports more pharmaceutical products from Ireland than from any other country -- nearly $50 billion last year. It won't be surprising if the Trump administration especially targets those ...